伴FLT3内部串联重复与MLL基因重排的34例急性髓系白血病的临床特征与预后
回顾性分析34例同时伴FLT3-ITD与MLL基因重排的急性髓系白血病患者,比较化疗、化疗联合靶向治疗及异基因造血干细胞移植的疗效。此类患者以M5多见,常伴高白细胞血症及多基因异常,化疗缓解率低、早期复发率高;接受异基因造血干细胞移植者3年总生存率为43.4%。
要点
- 34例中M5占35.3%,入院WBC>30×10^9/L者63.6%,多基因异常者67.6%。
- 2个疗程完全缓解率29.4%,完全缓解者早期复发率52.9%。
- 接受异基因造血干细胞移植者3年总生存率43.4%,3年无病生存率42.7%。
核心结论
- 同时伴FLT3-ITD与MLL基因异常的AML患者FAB分型以M5多见,常伴高白细胞血症、细胞遗传学异常及多基因异常。
- 此类患者化疗缓解率低、早期复发率高、长期生存率低;高白细胞血症、多基因异常可能是疗效差的重要原因,异基因造血干细胞移植可改善转归。
研究设计与样本
- 回顾性分析34例同时伴FLT3-ITD突变及MLL基因异常的AML患者,占同期住院AML患者的2.02%。
- 比较化疗、化疗加靶向药物治疗及异基因造血干细胞移植的疗效及影响因素。
主要发现
- 34例中位年龄41(4-71)岁,入院时WBC>30×10^9/L者占63.6%,WBC>50×10^9/L者占39.4%,FAB亚型以M5比例最高占35.3%。
- 仅有FLT3-ITD及MLL双基因异常者11例(32.4%),具FLT3及MLL以外1种及1种以上基因异常(多基因异常)者23例(67.6%)。
- 2个疗程完全缓解率为29.4%,7例(20.6%)化疗≥3个疗程后完全缓解,完全缓解患者早期复发率为52.9%。
- WBC>50×10^9/L者2个疗程完全缓解率为7.7%,多基因异常者2个疗程完全缓解率为5.4%,具有3种以上基因异常者无一例完全缓解。
- 34例2年总生存率为28.8%(95%CI 13.5%-46.0%),2年无病生存率为27.1%(95%CI 12.5%-44.0%);接受异基因造血干细胞移植者3年总生存率为43.4%(95%CI 13.7%-70.4%),3年无病生存率为42.7%(95%CI 13.4%-69.7%)。
关键数值与推荐
- 18例仅使用化疗或化疗加靶向药物治疗的患者中,17例在2年内死亡,1例放弃治疗后失访。
临床怎么用
- 原文结论认为异基因造血干细胞移植是有效治疗,可改善伴FLT3-ITD及MLL基因异常AML患者的预后与生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the clinical characteristics and prognosis of 34 cases of acute myeloid leukemia (AML) with FLT3 internal tandem duplication (FLT3-ITD) and MLL gene rearrangement. Methods: The clinical data of 34 AML patients with FLT3-ITD and MLL gene rearrangement was compared and analyzed for the therapeutic efficacy, prognostic factors when treated with chemotherapy, chemotherapy combined with targeted therapy or allogenic hematopoietic stem cell transplantation (allo-HSCT). Results: Of the thirty-four cases with median age 41 (4-71) years old, 63.6% presented with white blood cells (WBC) greater than 30×10(9)/L, 39.4% greater than 50 × 10(9)/L respectively on admission. M(5) (35.3%) made up the highest proportion. The cytogenetic abnormality reached 61.8%, of which the complex cytogenetic abnormality accounted for 11.8%. Eleven patients (32.35%) had both FLT3-ITD and MLL gene abnormalities. In addition to FLT3 and MLL abnormalities, 23 patients (67.6%) had one or more other gene abnormalities (multiple gene abnormalities). Of the 34 cases, 29.4% patients went into complete remission (CR) after two courses of chemotherapy. 20.6% (7 patients) went into CR after 3 or more courses of chemotherapy. The rate of early relapse in the CR group was 52.9%. Patients with WBC>50×10(9)/L or multiple gene abnormalities had a lower remission rate (7.7%, 5.4%) after two courses of chemotherapy. CR rate for the patients with more than three gene abnormalities was 0. The total 2-year overall survival (OS) in the 34 patients was 28.8% (95% CI 13.5%-46.0%) and the disease-free survival (DFS) was 27.1% (95% CI 12.5%-44.0%). Of the 18 patients treated with chemotherapy alone or chemotherapy combined with targeted therapy, 17 cases died within 2 years and 1 lost follow-up after giving up treatment. For the 16 patients received allo-HSCT, the 3-year OS was 43.4% (95% CI 13.7%-70.4%) and DFS 42.7% (95% CI 13.4%-69.7%). Conclusion: AML patients with FLT3-ITD and MLL gene rearrangement often presented with M(5), accompanied by hyperleukocytosis, cytogenetic or multiple gene abnormalities. Those patients were observed to have low response rate and high early relapse when treated with chemotherapy without allo-HSCT. Patients had multiple gene abnormalities may be an important poor prognostic factor. Allo-HSCT is an effective treatment which could significantly improve the prognosis and survival of AML patients with FLT3-ITD and MLL gene abnormalities. 目的: 探讨同时伴FLT3-ITD突变及MLL基因异常的急性髓系白血病(AML)患者的临床特征及转归。 方法: 回顾性分析34例同时伴FLT3-ITD突变及MLL基因异常的AML患者的临床资料,比较化疗、化疗加靶向药物治疗及allo-HSCT的疗效及影响因素。 结果: 34例同时伴FLT3-ITD突变及MLL基因异常的AML患者占同期住院AML患者的2.02%。入院时WBC>30×10(9)/L的患者占63.6%,其中WBC>50×10(9)/L者占39.4%。FAB亚型中以M(5)比例最高,占35.3%,染色体核型异常者达63.6%,其中复杂异常占12.1%。34例患者中仅有FLT3-ITD及MLL基因异常(双基因异常)者11例(32.4%),具FLT3及MLL以外的1种及1种以上的基因异常(多基因异常)者23例(67.6%)。34例患者2个疗程完全缓解(CR)率为29.4%,7例(20.6%)化疗≥3个疗程后CR,CR患者的早期复发率为52.9%。WBC>50×10(9)/L以及多基因异常的患者2个疗程CR率较低(7.7%、5.4%),其中具有3种以上基因异常的患者无一例CR。34例患者2年总生存(OS)率为28.8%(95%CI 13.5%~46.0%),2年无病生存(DFS)率为27.1%(95% CI 12.5%~44.0%)。18例仅使用化疗或化疗加靶向药物治疗的患者,17例在2年内死亡,1例放弃治疗后失访。接受allo-HSCT治疗的患者3年OS率为43.4%(95%CI 13.7%~70.4%),3年DFS率为42.7%(95% CI 13.4%~69.7%)。 结论: 同时伴FLT3-ITD突变及MLL基因异常的AML患者FAB分型以M(5)多见,常伴高白细胞血症、细胞遗传学异常及多基因异常。患者化疗缓解率低,早期复发率高,长期生存率低。高白细胞血症、多基因异常可能是此类患者疗效差的重要原因,allo-HSCT可改善患者的转归。.
引用
- Zhou JR, Zhang X, Zhao YL, et al. [Clinical characteristics and prognosis of 34 cases of acute myeloid leukemia with FLT3 internal tandem duplication and MLL gene rearrangement]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30369187. doi:10.3760/cma.j.issn.0253-2727.2018.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。